Chattem will launch new dietary formula "with an advanced heart formula to help reduce the risk of heart disease" in January 2006, the company announces Oct. 11. Garlique CardioAssist is intended for consumers with a moderate risk of developing heart disease and contains plant sterols, niacin, folic act and vitamins B6 and B12 "to help lower total and LDL cholesterol while maintaining health levels of HDL cholesterol," Chattem states. The product is expected to bring in fiscal year 2006 revenues of $3 mil. to $5 mil., the firm adds. NewBullFrog Mosquito Coast also is launching tooffer consumers 8 hours of mosquito repellency as well as SPF 30 protection. The product begins shipping in November to warmer regions such as Florida and Texas. Mosquito Coast will be packaged as a "convenient '2-in-1' fast drying spray" and carries a SRP of $8.99 for 4.7 oz. Chattem first announced the impending launch in a September third-quarter analyst call (1"The Tan Sheet" Sept. 26, 2005, p. 8)...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.
Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.
Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
